Embattled Biogen sells stake in biosimilars venture for $2.3B

Embattled Cambridge biotech Biogen Inc. will make some quick cash by selling its stake in a biosimilars venture it started more than 10 years ago with Samsung Bioepsis, a subsidiary of the Korean biopharmaceutical company Samsung Biologics.